Use of tacrolimus as the primary immunosuppression after renal transplant in Native Americans and Hispanics

Transplant Proc. 1998 Jun;30(4):1232-3. doi: 10.1016/s0041-1345(98)00222-x.
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Diabetes Mellitus / epidemiology
  • Diabetic Nephropathies / epidemiology
  • Diabetic Nephropathies / surgery
  • Ethnicity
  • Female
  • Follow-Up Studies
  • Graft Rejection / epidemiology
  • Hispanic or Latino*
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Indians, North American*
  • Kidney Failure, Chronic / etiology
  • Kidney Failure, Chronic / surgery
  • Kidney Transplantation / immunology*
  • Kidney Transplantation / mortality
  • Male
  • Middle Aged
  • Muromonab-CD3 / therapeutic use
  • New Mexico
  • Survival Rate
  • Tacrolimus / adverse effects
  • Tacrolimus / therapeutic use*

Substances

  • Immunosuppressive Agents
  • Muromonab-CD3
  • Tacrolimus